208 related articles for article (PubMed ID: 34330762)
1. High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies.
Çınar Ö; Brzezicha B; Grunert C; Kloetzel PM; Beier C; Peuker CA; Keller U; Pezzutto A; Busse A
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330762
[TBL] [Abstract][Full Text] [Related]
2. Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations.
Shen M; Chen S; Han X; Hao Y; Wang J; Li L; Chen T; Wang B; Zou L; Zhang T; Zhang W; Han X; Wang W; Yu H; Li K; Liu S; Jin A
Cancer Immunol Immunother; 2024 Jun; 73(8):150. PubMed ID: 38832948
[TBL] [Abstract][Full Text] [Related]
3. Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.
Jahn L; van der Steen DM; Hagedoorn RS; Hombrink P; Kester MG; Schoonakker MP; de Ridder D; van Veelen PA; Falkenburg JH; Heemskerk MH
Oncotarget; 2016 Nov; 7(47):77021-77037. PubMed ID: 27776339
[TBL] [Abstract][Full Text] [Related]
4. HLA class I-restricted
Nelde A; Walz JS; Kowalewski DJ; Schuster H; Wolz OO; Peper JK; Cardona Gloria Y; Langerak AW; Muggen AF; Claus R; Bonzheim I; Fend F; Salih HR; Kanz L; Rammensee HG; Stevanović S; Weber AN
Oncoimmunology; 2017; 6(3):e1219825. PubMed ID: 28405493
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities.
Weber ANR; Cardona Gloria Y; Çınar Ö; Reinhardt HC; Pezzutto A; Wolz OO
Cancer Immunol Immunother; 2018 Nov; 67(11):1797-1807. PubMed ID: 30203262
[TBL] [Abstract][Full Text] [Related]
6.
Yu X; Li W; Deng Q; Li L; Hsi ED; Young KH; Zhang M; Li Y
Cancer Res; 2018 May; 78(10):2457-2462. PubMed ID: 29703722
[TBL] [Abstract][Full Text] [Related]
7. MYD88 L265P mutation promoted malignant B cell resistance against T cell-mediated cytotoxicity via upregulating the IL-10/STAT3 cascade.
Qiu H; Gong S; Xu L; Cheng H; Gao L; Chen J; Hu X; Yang J
Int Immunopharmacol; 2018 Nov; 64():394-400. PubMed ID: 30253331
[TBL] [Abstract][Full Text] [Related]
8. Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers.
Li Q; Hu W; Liao B; Song C; Li L
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798537
[TBL] [Abstract][Full Text] [Related]
9. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
10. TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.
Jahn L; Hombrink P; Hagedoorn RS; Kester MG; van der Steen DM; Rodriguez T; Pentcheva-Hoang T; de Ru AH; Schoonakker MP; Meeuwsen MH; Griffioen M; van Veelen PA; Falkenburg JH; Heemskerk MH
Blood; 2017 Mar; 129(10):1284-1295. PubMed ID: 28053195
[TBL] [Abstract][Full Text] [Related]
11. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.
Sim MJW; Lu J; Spencer M; Hopkins F; Tran E; Rosenberg SA; Long EO; Sun PD
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12826-12835. PubMed ID: 32461371
[TBL] [Abstract][Full Text] [Related]
12. Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing.
Shafer P; Leung WK; Woods M; Choi JM; Rodriguez-Plata CM; Maknojia A; Mosquera A; Somes LK; Joubert J; Manliguez A; Ranjan R; Burt B; Lee HS; Zhang B; Fuqua S; Rooney C; Leen AM; Hoyos V
Cytotherapy; 2024 Mar; 26(3):266-275. PubMed ID: 38231165
[TBL] [Abstract][Full Text] [Related]
13. Oncogenically active MYD88 mutations in human lymphoma.
Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
[TBL] [Abstract][Full Text] [Related]
14. Frequency of MYD88 L256P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasm.
Shekhar R; Naseem S; Binota J; Varma N; Malhotra P
Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):231-239. PubMed ID: 33217360
[TBL] [Abstract][Full Text] [Related]
15. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
[TBL] [Abstract][Full Text] [Related]
16. Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.
Rath JA; Arber C
Cells; 2020 Jun; 9(6):. PubMed ID: 32570906
[TBL] [Abstract][Full Text] [Related]
17. Targeting KRAS
Ai Q; Li F; Zou S; Zhang Z; Jin Y; Jiang L; Chen H; Deng X; Peng C; Mou N; Wen C; Shen B; Zhan Q
Front Immunol; 2023; 14():1161538. PubMed ID: 37287989
[TBL] [Abstract][Full Text] [Related]
18. A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy.
Meeuwsen MH; Wouters AK; Jahn L; Hagedoorn RS; Kester MGD; Remst DFG; Morton LT; van der Steen DM; Kweekel C; de Ru AH; Griffioen M; van Veelen PA; Falkenburg JHF; Heemskerk MHM
Mol Ther; 2022 Feb; 30(2):564-578. PubMed ID: 34371177
[TBL] [Abstract][Full Text] [Related]
19. Avidity characterization of genetically engineered T-cells with novel and established approaches.
Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
[TBL] [Abstract][Full Text] [Related]
20. Detection of mutant antigen-specific T cell receptors against multiple myeloma for T cell engineering.
Okada M; Shimizu K; Nakazato H; Yamasaki S; Fujii SI
Mol Ther Methods Clin Dev; 2023 Jun; 29():541-555. PubMed ID: 37359417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
